PERSEPHONE: 6 vs. 12-month adjuvant trastuzumab in early breast cancer

Trastuzumab has revolutionized the treatment of HER2+ breast cancer; however, the benefit of a longer duration of this therapy is uncertain. The PERSEPHONE trial (ISRCTN52968807) looked at the efficac... Author: VJOncology Added: 07/27/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts